Limits...
Modified Pulsatilla decoction attenuates oxazolone-induced colitis in mice through suppression of inflammation and epithelial barrier disruption.

Wang X, Fan F, Cao Q - Mol Med Rep (2016)

Bottom Line: Assessment of clinical colitis and histological examination found that the administration of modified Pulsatilla decoction attenuated the severity of oxazolone‑induced colitis in mice.Measurement of cytokine concentration, western blotting and reverse transcription‑quantitative polymerase chain reaction demonstrated modified Pulsatilla decoction treatment significantly reduced the secretion of pro‑inflammatory cytokines and restored alterations in tight junction proteins in the colon tissues.Thus, the findings of the present study demonstrated that modified Pulsatilla decoction offers an effective therapeutic approach for the treatment of IBD and revealed the underlying mechanisms of action offered by modified Pulsatilla decoction.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China.

ABSTRACT
Inflammatory bowel diseases (IBDs) are chronic inflammatory gastrointestinal disorders caused by a dysregulated mucosal immune response and epithelial barrier disruption. Conventional treatment of IBD is currently limited to overcoming patient symptoms and is often associated with severe adverse effects from the drugs used. Modified Pulsatilla decoction has been used previously to treat ulcerative colitis (UC) in clinical practice in China, however, the underlying mechanism in the treatment of UC remains to be elucidated. In the present study, the efficiency and mechanisms of modified Pulsatilla decoction in the treatment of oxazolone‑induced colitis were investigated. Assessment of clinical colitis and histological examination found that the administration of modified Pulsatilla decoction attenuated the severity of oxazolone‑induced colitis in mice. Measurement of cytokine concentration, western blotting and reverse transcription‑quantitative polymerase chain reaction demonstrated modified Pulsatilla decoction treatment significantly reduced the secretion of pro‑inflammatory cytokines and restored alterations in tight junction proteins in the colon tissues. In addition, modified Pulsatilla decoction suppressed the activation of the nuclear factor‑κB signaling pathway. Thus, the findings of the present study demonstrated that modified Pulsatilla decoction offers an effective therapeutic approach for the treatment of IBD and revealed the underlying mechanisms of action offered by modified Pulsatilla decoction.

No MeSH data available.


Related in: MedlinePlus

Modified Pulsatilla decoction treatment attenuates the severity of oxazolone-induced colitis in mice. (A) Weight loss of oxazolone-induced colitis mice following treatment with modified Pulsatilla decoction or SASP. (B) DAI scores were measured following 7 days of treatment with modified Pulsatilla decoction or SASP. (C) Representative images from the hematoxylin and eosin-stained sections of the colon from the different groups of mice. Magnification, x200. Data are representative of three independent experiments and expressed as the mean ± standard deviation. *P<0.05 **P<0.01 vs. the control group. PBS, phosphate-buffered saline; SASP, sulfasalazine; DAI, disease activity index.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940073&req=5

f1-mmr-14-02-1173: Modified Pulsatilla decoction treatment attenuates the severity of oxazolone-induced colitis in mice. (A) Weight loss of oxazolone-induced colitis mice following treatment with modified Pulsatilla decoction or SASP. (B) DAI scores were measured following 7 days of treatment with modified Pulsatilla decoction or SASP. (C) Representative images from the hematoxylin and eosin-stained sections of the colon from the different groups of mice. Magnification, x200. Data are representative of three independent experiments and expressed as the mean ± standard deviation. *P<0.05 **P<0.01 vs. the control group. PBS, phosphate-buffered saline; SASP, sulfasalazine; DAI, disease activity index.

Mentions: To investigate the therapeutic effect of modified Pulsatilla decoction on IBD, the present study induced experimental colitis in mice via skin pre-sensitization and colonic administration of oxazolone. The results demonstrated that the mice injected with oxazolone developed experimental colitis with severe weight loss (Fig. 1A), severe hunching, lethargy, piloerection and diarrhea, and showed a significantly increased DAI score, compared with the normal group (P<0.01). Although there were no differences between the Pulsatilla decoction-treated mice and the SASP-treated mice, oral administration of modified Pulsatilla decoction and SASP significantly attenuated the severity of oxazolone-induced colitis, which showed decreased DAI scores, compared with the untreated group (P<0.01; Fig. 1B).


Modified Pulsatilla decoction attenuates oxazolone-induced colitis in mice through suppression of inflammation and epithelial barrier disruption.

Wang X, Fan F, Cao Q - Mol Med Rep (2016)

Modified Pulsatilla decoction treatment attenuates the severity of oxazolone-induced colitis in mice. (A) Weight loss of oxazolone-induced colitis mice following treatment with modified Pulsatilla decoction or SASP. (B) DAI scores were measured following 7 days of treatment with modified Pulsatilla decoction or SASP. (C) Representative images from the hematoxylin and eosin-stained sections of the colon from the different groups of mice. Magnification, x200. Data are representative of three independent experiments and expressed as the mean ± standard deviation. *P<0.05 **P<0.01 vs. the control group. PBS, phosphate-buffered saline; SASP, sulfasalazine; DAI, disease activity index.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940073&req=5

f1-mmr-14-02-1173: Modified Pulsatilla decoction treatment attenuates the severity of oxazolone-induced colitis in mice. (A) Weight loss of oxazolone-induced colitis mice following treatment with modified Pulsatilla decoction or SASP. (B) DAI scores were measured following 7 days of treatment with modified Pulsatilla decoction or SASP. (C) Representative images from the hematoxylin and eosin-stained sections of the colon from the different groups of mice. Magnification, x200. Data are representative of three independent experiments and expressed as the mean ± standard deviation. *P<0.05 **P<0.01 vs. the control group. PBS, phosphate-buffered saline; SASP, sulfasalazine; DAI, disease activity index.
Mentions: To investigate the therapeutic effect of modified Pulsatilla decoction on IBD, the present study induced experimental colitis in mice via skin pre-sensitization and colonic administration of oxazolone. The results demonstrated that the mice injected with oxazolone developed experimental colitis with severe weight loss (Fig. 1A), severe hunching, lethargy, piloerection and diarrhea, and showed a significantly increased DAI score, compared with the normal group (P<0.01). Although there were no differences between the Pulsatilla decoction-treated mice and the SASP-treated mice, oral administration of modified Pulsatilla decoction and SASP significantly attenuated the severity of oxazolone-induced colitis, which showed decreased DAI scores, compared with the untreated group (P<0.01; Fig. 1B).

Bottom Line: Assessment of clinical colitis and histological examination found that the administration of modified Pulsatilla decoction attenuated the severity of oxazolone‑induced colitis in mice.Measurement of cytokine concentration, western blotting and reverse transcription‑quantitative polymerase chain reaction demonstrated modified Pulsatilla decoction treatment significantly reduced the secretion of pro‑inflammatory cytokines and restored alterations in tight junction proteins in the colon tissues.Thus, the findings of the present study demonstrated that modified Pulsatilla decoction offers an effective therapeutic approach for the treatment of IBD and revealed the underlying mechanisms of action offered by modified Pulsatilla decoction.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China.

ABSTRACT
Inflammatory bowel diseases (IBDs) are chronic inflammatory gastrointestinal disorders caused by a dysregulated mucosal immune response and epithelial barrier disruption. Conventional treatment of IBD is currently limited to overcoming patient symptoms and is often associated with severe adverse effects from the drugs used. Modified Pulsatilla decoction has been used previously to treat ulcerative colitis (UC) in clinical practice in China, however, the underlying mechanism in the treatment of UC remains to be elucidated. In the present study, the efficiency and mechanisms of modified Pulsatilla decoction in the treatment of oxazolone‑induced colitis were investigated. Assessment of clinical colitis and histological examination found that the administration of modified Pulsatilla decoction attenuated the severity of oxazolone‑induced colitis in mice. Measurement of cytokine concentration, western blotting and reverse transcription‑quantitative polymerase chain reaction demonstrated modified Pulsatilla decoction treatment significantly reduced the secretion of pro‑inflammatory cytokines and restored alterations in tight junction proteins in the colon tissues. In addition, modified Pulsatilla decoction suppressed the activation of the nuclear factor‑κB signaling pathway. Thus, the findings of the present study demonstrated that modified Pulsatilla decoction offers an effective therapeutic approach for the treatment of IBD and revealed the underlying mechanisms of action offered by modified Pulsatilla decoction.

No MeSH data available.


Related in: MedlinePlus